



HUTCHISON CHINA MEDITECH

## Press Release

### Chi-Med to Present at the 39<sup>th</sup> Annual JP Morgan Healthcare Conference

**Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, December 22, 2020:** Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 39<sup>th</sup> Annual JP Morgan Healthcare Conference taking place virtually on Monday January 11, 2021 at 8 a.m. EST (1 p.m. GMT / 9 p.m. HKT).

The presentation will be webcast live and can be accessed at [www.chi-med.com](http://www.chi-med.com) in the Shareholder Information section under “Events, Circulars & Forms.” Investors interested in listening to the live webcast should log on before the start time to download any software required. A replay of the event will be available shortly thereafter, for 90 days.

#### About Chi-Med

Chi-Med (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of nine cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: [www.chi-med.com](http://www.chi-med.com).

#### Forward-Looking Statements

*This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med’s filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.*

#### CONTACTS

##### Investor Enquiries

Mark Lee, Senior Vice President	+852 2121 8200
Annie Cheng, Vice President	+1 (973) 567 3786

##### Media Enquiries

<b>Americas</b> – Brad Miles, Solebury Trout	+1 (917) 570 7340 (Mobile) <a href="mailto:bmiles@troutgroup.com">bmiles@troutgroup.com</a>
<b>Europe</b> – Ben Atwell / Alex Shaw, FTI Consulting	+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) <a href="mailto:Chi-Med@fticonsulting.com">Chi-Med@fticonsulting.com</a>
<b>Asia</b> – Joseph Chi Lo / Zhou Yi, Brunswick	+852 9850 5033 (Mobile), <a href="mailto:jlo@brunswickgroup.com">jlo@brunswickgroup.com</a> / +852 9783 6894 (Mobile), <a href="mailto:yzhou@brunswickgroup.com">yzhou@brunswickgroup.com</a>

##### Nominated Advisor

Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited	+44 (20) 7886 2500
---	--------------------